Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
about
Lung Cancer Gene Signatures and Clinical PerspectivesCost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.Systems biology approaches to develop innovative strategies for lung cancer therapy.Prognostic markers in lung cancer: is it ready for prime time?Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy.Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis.Lung Cancer Staging and Prognosis.An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.Prognostic and predictive biomarkers post curative intent therapy.Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma.Generating a robust prediction model for stage I lung adenocarcinoma recurrence after surgical resection.Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
P2860
Q28387769-36FD0540-7948-4AB3-A873-62A4E132FF26Q33577838-387E04C7-3931-4713-AA56-6C6576FA1C5FQ33720233-FF5B3BF1-4CA3-4899-8A6C-A26ED0E01604Q35200555-F0DBC453-0C41-4BA3-A720-74BE77548571Q35739691-E3959F91-F25C-402B-8B77-C86F9076ABC5Q37610799-047D2290-2E34-4D8A-8B82-2F1496182CFFQ37696112-533A9E0D-F0B3-4A90-A120-917EFC9574E6Q38323055-0168DCF6-1D5A-4500-8CB1-5D0C99A09FC4Q38716717-E89239D5-DE21-4F09-BABB-BAF6A96E3254Q38830349-AA8E0899-477D-4B11-9FD6-F921890A51BBQ39180729-E5F15EF4-CCFB-42FE-B420-7D1504B3BA5CQ43026297-9BC80A28-583E-47A6-8E40-B306EE901D05Q46046685-E35495E4-CB83-482C-80C5-941998136A9DQ46071206-70B91382-95BD-48C4-A0AE-3F7478ECD77EQ47130427-6DB69AA1-208C-4CA7-B06F-D7ED66615D94Q55159440-A260C999-B6F1-49CC-89F2-0FA05BB79A0A
P2860
Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genomic signatures for predict ...... ith non-small-cell lung cancer
@ast
Genomic signatures for predict ...... ith non-small-cell lung cancer
@en
Genomic signatures for predict ...... ith non-small-cell lung cancer
@nl
type
label
Genomic signatures for predict ...... ith non-small-cell lung cancer
@ast
Genomic signatures for predict ...... ith non-small-cell lung cancer
@en
Genomic signatures for predict ...... ith non-small-cell lung cancer
@nl
prefLabel
Genomic signatures for predict ...... ith non-small-cell lung cancer
@ast
Genomic signatures for predict ...... ith non-small-cell lung cancer
@en
Genomic signatures for predict ...... ith non-small-cell lung cancer
@nl
P2860
P356
P1433
P1476
Genomic signatures for predict ...... ith non-small-cell lung cancer
@en
P2093
Ryan K Van Laar
P2860
P2888
P356
10.1186/1755-8794-5-30
P577
2012-07-02T00:00:00Z
P5875
P6179
1009884395